Lipid Management in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2013 on lipid management and treatment of all adults and children with chronic kidney disease (CKD). All forms of CKD are included (non-dialysis-dependent, dialysis-dependent, and kidney transplant recipients). METHODS: The KDIGO Lipid Guideline Development Work Group defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence that had been summarized by an evidence review team. Searches of the English-language literature were conducted through August 2011 and supplemented by targeted searches through June 2013. Final modification of the guidelines was informed by the KDIGO Board of Directors and a public review process involving registered stakeholders. RECOMMENDATIONS: The full guideline includes 13 recommendations; a key element was the recommendation for statin or statin with ezetimibe treatment of adults aged 50 years or older with estimated glomerular filtration rates less than 60 mL/min/1.73 m2 but not treated with long-term dialysis or kidney transplantation. This synopsis focuses on 8 recommendations pertinent to assessment of lipid status and treatment with a statin-based regimen in adults.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on the evidence for lipid management in patients with CKD, the Kidney Disease: Improving Global Outcomes (KDIGO) organization developed an updated clinical practice guideline for lipid management in CKD. 399”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [399]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Stevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Self-citationAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Self-citationADOLESCENTS, E. P. O. I. G. F. C. H. A. R. R. I. C. A. (2011) · Pediatrics · doi:10.1542/peds.2009-2107c · Cited by 2,585
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Self-citationRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Lowrie, E. G., & Lew, N. L. (1990) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70364-5 · Cited by 1,976
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar, N. S., McMurray, J. J. V., Velazquez, E. J., Solomon, S. D., Kober, L., Rouleau, J.-L., White, H. D., Nordlander, R., Maggioni, A., Dickstein, K., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041365 · Cited by 1,917
Assmann, G., Cullen, P., & Schulte, H. (2002) · Circulation · doi:10.1161/hc0302.102575 · Cited by 1,541
Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2
Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J., Minhas, R., Sheikh, A., & Brindle, P. (2008) · BMJ · doi:10.1136/bmj.39609.449676.25 · Cited by 1,459
Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13638-0 · Cited by 919
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Liu, Y., Coresh, J., Eustace, J. A., Longenecker, J. C., Jaar, B., Fink, N. E., Tracy, R. P., Powe, N. R., & Klag, M. J. (2004) · JAMA · doi:10.1001/jama.291.4.451 · Cited by 777 · cited 1×
“Low-density lipoprotein cholesterol is not suitable for assessing coronary risk in persons with CKD: Although higher levels of LDL cholesterol are associated with higher risk, dialysis patients with the lowest levels of LDL cholesterol and total cholesterol are also at very high risk for all-cause and cardiovascular m…”
BackgroundWoodward, M., Brindle, P., & Tunstall-Pedoe, H. (2007) · Heart · doi:10.1136/hrt.2006.108167 · Cited by 667
Bachorik, P. S., & Ross, J. W. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1414 · Cited by 412 · cited 1×
“tion as well (26), but fasting specimens will be needed if significant lipid abnormalities are found, especially severe hypertriglyceridemia (26–28).”
BackgroundAuthors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs254 · Cited by 390
Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients
Iseki, K., Yamazato, M., Tozawa, M., & Takishita, S. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00324.x · Cited by 383
Ezekowitz, J., McAlister, F. A., Humphries, K. H., Norris, C. M., Tonelli, M., Ghali, W. A., & Knudtson, M. L. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.06.072 · Cited by 377
Self-citationPalmer, S. C., Craig, J. C., Navaneethan, S. D., Tonelli, M., Pellegrini, F., & Strippoli, G. F. M. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-4-201208210-00007 · Cited by 359 · cited 2×
“In general, these analyses suggest that statins reduce the relative risk for cardiovascular events to a similar extent among patients with and without CKD but that the absolute benefit of treatment is larger in the former because of the greater baseline risk (12).”
Self-citationHyperlipidemia in patients with chronic renal disease
Kasiske, B. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820472 · Cited by 281 · cited 1×
“The major determinants of dyslipidemia in CKD patients are GFR, the presence of diabetes mellitus, severity of proteinuria, use of immunosuppressive agents, method of renal replacement, comorbidity, and nutritional status (25).”
BackgroundColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., & Fuller, J. H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.03.022 · Cited by 255
Association between Serum Lipids and Survival in Hemodialysis Patients and Impact of Race
Kilpatrick, R. D., McAllister, C. J., Kovesdy, C. P., Derose, S. F., Kopple, J. D., & Kalantar-Zadeh, K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006070795 · Cited by 233 · cited 1×
“An additional weakness of this approach is that it will lead to underutilization of statins in CKD patients with low LDL cholesterol, who are at very high cardiovascular risk (31).”
BackgroundWarnick, G. R., & Wood, P. D. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1427 · Cited by 212
Tonelli, M., Jose, P., Curhan, G., Sacks, F., Braunwald, E., & Pfeffer, M. (2006) · BMJ · doi:10.1136/bmj.38814.566019.2f · Cited by 193
Self-citationHou, W., Lv, J., Perkovic, V., Yang, L., Zhao, N., Jardine, M. J., Cass, A., Zhang, H., & Wang, H. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht065 · Cited by 192 · cited 1×
“Even if statins truly do prevent cardiovascular events in prevalent dialysis patients, the magnitude of any relative reduction in risk seems substantially smaller than in earlier stages of CKD (12), although this may still translate into a clinically meaningful absolute benefit (22).”
BackgroundLatif, F., Kleiman, N. S., Cohen, D. J., Pencina, M. J., Yen, C.-H., Cutlip, D. E., Moliterno, D. J., Nassif, D., Lopez, J. J., & Saucedo, J. F. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.06.012 · Cited by 163
Epidemiology of cardiovascular risk factors in chronic renal disease.
Coresh, J., Longenecker, J. C., Miller, E. R., Young, H., & Klag, M. J. (1998) · PubMed · Cited by 160
Stein, E. A., & Myers, G. L. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1421 · Cited by 160
März, W., Genser, B., Drechsler, C., Krane, V., Grammer, T. B., Ritz, E., Stojakovic, T., Scharnagl, H., Winkler, K., Holme, I., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09121010 · Cited by 145
Self-citationAssociation between LDL-C and Risk of Myocardial Infarction in CKD
Tonelli, M., Muntner, P., Lloyd, A., Manns, B., Klarenbach, S., Pannu, N., James, M., & Hemmelgarn, B. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012080870 · Cited by 139
Self-citationMonitoring Cholesterol Levels: Measurement Error or True Change?
Glasziou, P. P., Irwig, L., Heritier, S., Simes, R. J., Tonkin, A., & for the LIPID Study Investigators (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00005 · Cited by 122 · cited 2×
“8 mmol/L [ 30 mg/dL] for total cholesterol)—and therefore, such follow-up measurements may not reliably indicate good or poor compliance (34).”
BackgroundHayward, R. A., & Krumholz, H. M. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.964676 · Cited by 122 · cited 2×
“Given the lack of data to support this approach in populations with and without CKD (32), the substantial within-person variability in LDL cholesterol measurements (33) and the potential for medication-related toxicity (including direct effects on muscle and liver, and indirect effects mediated through drug interactio…”
BackgroundDiabetes and Coronary Risk Equivalency
Grundy, S. M. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1904 · Cited by 53 · cited 1×
“To maximize the ratio of benefits to harms and costs, future coronary risk is considered an important potential determinant of the decision to prescribe cholesterollowering treatment (2).”
BackgroundKrane, V., Winkler, K., Drechsler, C., Lilienthal, J., März, W., & Wanner, C. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.06.029 · Cited by 52
Self-citation(2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)70056-0 · Cited by 51
Lipid re-screening: what is the best measure and interval?
Takahashi, O., Glasziou, P. P., Perera, R., Shimbo, T., Suwa, J., Hiramatsu, S., & Fukui, T. (2010) · Heart · doi:10.1136/hrt.2009.172619 · Cited by 46 · cited 1×
“Given the lack of data to support this approach in populations with and without CKD (32), the substantial within-person variability in LDL cholesterol measurements (33) and the potential for medication-related toxicity (including direct effects on muscle and liver, and indirect effects mediated through drug interactio…”
BackgroundChiang, C.-K., Ho, T.-I., Hsu, S.-P., Peng, Y.-S., Pai, M.-F., Yang, S.-Y., Hung, K.-Y., & Tsai, T.-J. (2005) · Blood Purification · doi:10.1159/000083529 · Cited by 39
Research works printed but not linked: 1
- Coresh J, 1998, J Am Soc Nephrol, 9, S24
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Chronic Kidney Disease Diagnosis and Management: A Review
Chen, T. K., Knicely, D. H., & Grams, M. E. (2019) · JAMA · doi:10.1001/jama.2019.14745 · Cited by 1,811
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Metadata
- Authors
- Tonelli, M., Wanner, C., & for the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members*
- Affiliations
- University of Alberta (CA)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2014-02-04
- Volume
- 160
- Issue
- 3
- Pages
- 182-189
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2159036586
- Cited by
- 226
- References
- 41
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 18 · 2023: 11 · 2022: 15 · 2021: 8 · 2020: 17 · 2019: 19 · 2018: 21 · 2017: 12 · 2016: 16 · 2015: 35 · 2014: 24
- FWCI
- 28.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- chronic kidney disease, lipid control, statins, ezetimibe, KDIGO guidelines, hypercholesterolemia, estimated glomerular filtration rate, dialysis, kidney transplantation, cardiovascular risk
- MeSH terms
- Adult, Algorithms, Child, Coronary Disease, Glomerular Filtration Rate, Humans, Cholesterol, LDL, Middle Aged, Risk Factors, Biomarkers, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Guideline Adherence, Dyslipidemias, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.